Literature DB >> 33582561

METTL3/IGF2BP1/CD47 contributes to the sublethal heat treatment induced mesenchymal transition in HCC.

Zhuoyang Fan1, Yang Gao2, Wei Zhang1, Guowei Yang1, Pingping Liu1, Ligang Xu1, Jianhua Wang1, Zhiping Yan1, Hong Han3, Rong Liu4, Minfeng Shu5.   

Abstract

Microwave ablation is a first-line treatment of small hepatocellular carcinoma (HCC), while incomplete ablation induces recurrence and metastasis. However, its underlying mechanism remains largely unexplored. Here we reported that sublethal heat treatment (46 °C) strongly promoted migration and EMT transition in HCC cells. Mechanistic investigation revealed that compared with 37 °C, HCC cells treated with 46 °C expressed higher level of CD47. Knockdown of CD47 significantly attenuated sublethal heat treatment stimulated migration and EMT transition. In addition, METTL3 which is the key enzyme of m6A modification was also induced by 46 °C treatment and triggered CD47 expression in HCC cells. Moreover, CD47 mRNA degradation was further proved to be stabled in the IGF2BP1-dependent manner. Importantly, sublethal heat treatment stimulated CD47 expression and EMT transition were also confirmed in patient-derived organoid. Taken together, our study suggests that METTL3/IGF2BP1/CD47 mediated EMT transition contributes to the incomplete ablation induced metastasis in HCC cells. Moreover, these findings identify the METTL3/IGF2BP1/CD47 axis as a potential therapeutic target for the microwave ablation and shed new lights on the crosstalk between incomplete heat ablation and RNA methylation.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD47; Hepatocellular carcinoma; IGF2BP1; METTL3; Patient-derived organoid

Year:  2021        PMID: 33582561     DOI: 10.1016/j.bbrc.2021.01.085

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  RNA methylation regulators contribute to poor prognosis of hepatocellular carcinoma associated with the suppression of bile acid metabolism: a multi-omics analysis.

Authors:  Tao Zhang; Jian Gu; Xinyi Wang; Jiajia Luo; Jing Yan; Kailin Cai; Huili Li; Yingli Nie; Xiangdong Chen; Jiliang Wang
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

Review 2.  N6-methyladenosine (m6A) RNA modification in tumor immunity.

Authors:  Siyi Zheng; Hui Han; Shuibin Lin
Journal:  Cancer Biol Med       Date:  2022-03-08       Impact factor: 5.347

Review 3.  An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation.

Authors:  Yusheng Guo; Yanqiao Ren; Xiangjun Dong; Xuefeng Kan; Chuansheng Zheng
Journal:  J Hepatocell Carcinoma       Date:  2022-04-26

Review 4.  The role of RNA modification in hepatocellular carcinoma.

Authors:  Qiang Feng; Dongxu Wang; Tianyi Xue; Chao Lin; Yongjian Gao; Liqun Sun; Ye Jin; Dianfeng Liu
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

5.  Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11.

Authors:  Zhuoyang Fan; Guowei Yang; Wei Zhang; Qian Liu; Guangqin Liu; Pingping Liu; Ligang Xu; Jianhua Wang; Zhiping Yan; Hong Han; Rong Liu; Minfeng Shu
Journal:  J Cell Mol Med       Date:  2021-10-05       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.